8-K
filed April 14, 2023, 7:59 PM ET
CIK 0001827506
other material
confidence high
sentiment negative
materiality 0.90
Tourmaline Bio, Inc.: restructuring charge — Talaris eliminates ~95% of remaining workforce; CEO and three other executives depart
Tourmaline Bio, Inc.
- April 2023 reduction of ~80 employees (95% of remaining staff); total severance costs estimated at $8.7M through Q2 2023.
- CEO Scott Requadt, CMO Nancy Krieger, CTO Michael Zdanowski, and CHRO Andrew Farnsworth all leaving company.
- CFO Mary Kay Fenton enters retention agreement; eligible for cash bonus upon strategic transaction or liquidation.
- Prior February reduction cut ~1/3 of workforce; company continues evaluating strategic alternatives.
- Reduction substantially complete by May 26, 2023; WARN Act severance provided.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Scott Requadt resigned as President and Chief Executive Officer at Tourmaline Bio, Inc..
- Action
- resigned
- Role
- President and Chief Executive Officer
Exact text from the filing
Scott Requadt, President and Chief Executive Officer, effective May 26, 2023
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Andrew Farnsworth resigned as Chief Human Resources Officer at Tourmaline Bio, Inc..
- Action
- resigned
- Role
- Chief Human Resources Officer
Exact text from the filing
Andrew Farnsworth, Chief Human Resources Officer, effective May 26, 2023
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Michael Zdanowski resigned as Chief Technology Officer at Tourmaline Bio, Inc..
- Action
- resigned
- Role
- Chief Technology Officer
Exact text from the filing
Michael Zdanowski, Chief Technology Officer, effective April 28, 2023
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Nancy Krieger resigned as Chief Medical Officer at Tourmaline Bio, Inc..
- Action
- resigned
- Role
- Chief Medical Officer
Exact text from the filing
Nancy Krieger, Chief Medical Officer, effective April 28, 2023
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.9
Tourmaline Bio, Inc. announced a restructuring with charges of approximately $5.8 million (approximately 80 additional employees, or approximately 95% of the Company's remaining workforce).
- Type
- restructuring
- Charge
- approximately $5.8 million
- Headcount
- approximately 80 additional employees, or approximately 95% of the Company's remaining workforce
Exact text from the filing
the Company estimates it will incur cash-based severance and other employee termination-related costs of approximately $5.8 million in the second quarter of 2023 related to the April Reduction in Force
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.